Fluarix Trivalent Influenza Vaccine

AvianA/H5N1 subtypeCanineEquineSwineA/H1N1 subtype A/H5N1 subtype A/H1N1 subtype 2009 pandemicPandemrixLive attenuatedSeasonal flu vaccine brands Pandemrix AmantadineBaloxavir marboxilLaninamivirOseltamivirPeramivirRimantadineUmifenovirZanamivir 1889–1890 Russian flu1918 Spanish flu1957–1958 Asian flu1968 Hong Kong flu1977 Russian flu2009 swine flu 1976 swine flu2006 H5N1 India2007 Australian equine2007 Bernard Matthews H5N12008 West Bengal2015 United States H5N2 outbreak2020–2023 H5N8 outbreak Flu seasonInfluenza evolutionInfluenza researchInfluenza-like illnessVaccine reformulations vte Since 1999, theWorld Health Organization(WHO) has issuedannual recommendations for influenza vaccine formulations.​‍​​​​​‍​‍‍‍‍​‍‍ Onereformulation of the influenza vaccineis for theNorthern Hemisphere, and the other is for theSouthern Hemisphere.Both recommendations are trivalent, i.e. featuring three strains. Since the 2012–2013 season, the WHO recommendations have also included the formulation of an annual quadrivalent vaccine, featuring an additionalstrainofInfluenza B virus, B/Yamagata. Due to the widespread use ofnon-pharmaceutical interventionsat the beginning of theCOVID-19pandemic, the B/Yamagata influenza lineage has not been isolated since March 2020, and may have been eradicated. Starting with the 2024 Southern Hemisphere influenza season, the WHO and other regulatory bodies have removed this strain from influenza vaccine recommendations.